Featured Research

from universities, journals, and other organizations

Cancer: Key mechanism in the control of cell motility revealed

Date:
October 29, 2010
Source:
Institut de recherches cliniques de Montreal
Summary:
Scientists have identified a novel molecular mechanism in the control of cell motility. This research could eventually lead to the development of new cancer-treating drugs that could block the spread of tumors (metastasis).

A team of scientists at the Institut de recherches cliniques de Montréal (IRCM) led by Dr. Jean-François Côté, Director of the Cytoskeletal Organization and Cell Migration research unit, identified a novel molecular mechanism in the control of cell motility. Their findings were published online October 28 in Current Biology. This scientific breakthrough could eventually lead to the development of new cancer-treating drugs that could block the spread of tumours (metastasis).

"As many as 90% of cancer patient deaths are attributable to metastasis, which explains the importance of understanding the molecular mechanisms at the basis of this harmful process," says Dr. Côté. "This is why, over the past few years, we have focused our research on DOCK180, a protein involved in intracellular signalling networks, and more particularly on the DOCK180/Rac1 signalling pathway, which is suspected to be a key mediator of tumour metastasis."

Unlike normal cells that migrate throughout embryonic and adult life to perform their specialized functions, cancer cells metastasize in order to lethally spread throughout the body. At a molecular level, DOCK180 specifically activates the small Rac1 protein, which, in turn, modifies a cell's shape and promotes cell motility and invasion. Dr. Côté's team had previously demonstrated in detail how DOCK180, with the help of its binding partner ELMO, acts on Rac1 to promote robust cell migration.

"We knew that this signalling pathway had to be regulated to prevent uncontrolled cell migration in normal conditions, but until now, the mechanisms involved had been eluding us and other scientists," explains Manishha Patel, a PhD student in Dr. Côté's laboratory and co-author of the study. "With our recent findings, we demonstrated that the ELMO protein closes in on itself to enter a repressed state, thus preventing the activation of the DOCK180/Rac pathway."

"Our team identified three regions in ELMO that allow it to toggle between a closed/inactive and open/active shape," adds Dr. Yoran Margaron, a postdoctoral fellow in the same research unit and one of the article's co-authors. "We showed that if we disrupt ELMO's regulatory feature and maintain the protein in an open state, we can fully activate the DOCK180/Rac pathway and significantly increase the migration potential of cells."

The researchers' next step is to investigate the regulation of ELMO in cancer cells. Based on their latest findings, they will attempt to maintain ELMO in a repressed state within cancer cells to prevent metastasis, which could have a major impact on the development of potential cancer treatments.

This research project was supported by the Canadian Institutes of Health Research (CIHR) and the Canadian Foundation for Innovation (CFI). Other collaborators for this study include Nadine Fradet, Qi Yang and Brian Wilkes from the IRCM, as well as Dr. Michel Bouvier from the Institut de recherche en immunologie et en cancérologie (IRIC), and Dr. Kay Hoffman from Miltenyi Biotec in Germany.


Story Source:

The above story is based on materials provided by Institut de recherches cliniques de Montreal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Manishha Patel, Yoran Margaron, Nadine Fradet, Qi Yang, Brian Wilkes, Michel Bouvier, Kay Hofmann and Jean-François Côté. An Evolutionarily Conserved Autoinhibitory Molecular Switch in ELMO Proteins Regulates Rac Signaling. Current Biology, October 28, 2010 DOI: 10.1016/j.cub.2010.10.028

Cite This Page:

Institut de recherches cliniques de Montreal. "Cancer: Key mechanism in the control of cell motility revealed." ScienceDaily. ScienceDaily, 29 October 2010. <www.sciencedaily.com/releases/2010/10/101028152504.htm>.
Institut de recherches cliniques de Montreal. (2010, October 29). Cancer: Key mechanism in the control of cell motility revealed. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/10/101028152504.htm
Institut de recherches cliniques de Montreal. "Cancer: Key mechanism in the control of cell motility revealed." ScienceDaily. www.sciencedaily.com/releases/2010/10/101028152504.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins